thyrointegrin antagonist-PEG-N-benzyl guanidine (NanoPharmaceuticals)

N/A

Report date: 2025/01/26 15:55:33
NME

Base Information

Drug Namethyrointegrin antagonist-PEG-N-benzyl guanidine (NanoPharmaceuticals)
Drug Alias NameN-benzyl guanidine and thyrointegrin alpha-v beta-3 receptor antagonist conjugate (NanoPharmaceuticals)BG-PEG-TAT
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonistsNorepinephrine transporter inhibitors
TargetsNorepinephrine transporterIntegrin alpha-V/beta-3
Therapy Area/IndicationsNeuroendocrine TumorsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNanoPharmaceuticals LLC
China Registration ClassN/A

Develop Information

Active CompaniesNanoPharmaceuticals LLC
Inactive CompaniesN/A
Active IndicationsNeuroendocrine TumorsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A